

Research Article

Functional Characterization of the Canine Heme-Regulated eIF2 α Kinase: Regulation of Protein Synthesis

Kimon C. Kanelakis,¹ Jayashree Pyati,¹ Pamela C. Wagaman,¹ Jui Chang Chuang,^{1,2} Young Yang,¹ and Nigel P. Shankley¹

¹ Department of Internal Medicine, Johnson & Johnson Pharmaceutical Research & Development L.L.C., Merryfield Row 3210, San Diego, CA 92121, USA

² Shire HGT, 700 Main St., Cambridge, MA 02139, USA

Correspondence should be addressed to Kimon C. Kanelakis, kkanelak@its.jnj.com

Received 4 March 2009; Accepted 9 April 2009

Recommended by George F. Atweh

The heme-regulated inhibitor (HRI) negatively regulates protein synthesis by phosphorylating eukaryotic initiation factor-2 α (eIF2 α) thereby inhibiting protein translation. The importance of HRI in regulating hemoglobin synthesis in erythroid cells makes it an attractive molecular target in need of further characterization. In this work, we have cloned and expressed the canine form of the HRI kinase. The canine nucleotide sequence has 86%, 82%, and 81% identity to the human, mouse, and rat HRI, respectively. It was noted that an isoleucine residue in the ATP binding site of human, rat, and mouse HRI is replaced by a valine in the canine kinase. The expression of canine HRI protein by in vitro translation using wheat germ lysate or in Sf9 cells using a baculovirus expression system was increased by the addition of hemin. Following purification, the canine protein was found to be 72 kD and showed kinase activity determined by its ability to phosphorylate a synthetic peptide substrate. Quercetin, a kinase inhibitor known to inhibit mouse and human HRI, inhibits canine HRI in a concentration-dependent manner. Additionally, quercetin is able to increase de novo protein synthesis in canine reticulocytes. We conclude that the canine is a suitable model species for studying the role of HRI in erythropoiesis.

Copyright © 2009 Kimon C. Kanelakis et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

1. Introduction

Heme-regulated inhibitor (HRI) is an eIF2 α kinase, which belongs to the eIF2 α kinase subfamily [1] that includes the double-stranded RNA-dependent eIF2 α kinase (PKR), the general control of nitrogen metabolism kinase (GCN2), and the endoplasmic reticulum resident kinase, PKR-related kinase (PERK), which is identical to the enzyme pancreatic eIF2 α kinase (PEK) that is highly expressed in pancreas [2]. Sequence comparison between HRI and other eIF2 α kinases reveals that the eIF2 α kinases share some degree of homology in their kinase catalytic domains. However, between the N- and C-lobes HRI has a distinct kinase insert that contains a heme binding site [3]. Kinase activity of HRI is modulated by binding of heme to the heme-binding domains located at its kinase insert and the amino terminus. As an eIF2 α kinase, HRI specifically phosphorylates eIF2 α at residue Serine 51

[4], blocking GTP exchange required for the recycling of eIF2, and thus inhibits protein synthesis [5]. Because HRI is predominantly expressed in erythroid cells, HRI exerts its kinase activity to regulate the synthesis of hemoglobin [6].

Phenotypic changes in HRI knockout mice show that HRI is nonessential, but plays an important regulatory role by dictating hemoglobin synthesis in erythroid cells [1]. Notably, in the absence of HRI kinase activity, reticulocytes obtained from HRI-deficient mice had a higher rate of protein synthesis. The importance of HRI in the pathophysiology of heme-deficiency disorders such as anemia of iron deficiency, protoporphyria, and β -thalassemia has been recently shown in animal models [7].

Interestingly, HRI does not exist in yeast, *Drosophila melanogaster*, and *C. elegans* [5, 8]. It is postulated that HRI has evolved during the development of the circulation to meet the increasing demand for oxygen in larger organisms.

Alignment of the amino acids of HRI from human, mouse, rat, and rabbit [8] reveals that HRI is conserved throughout evolution among these mammals with approximately 77% identity and 83% homology. Because of the importance of HRI in regulating hemoglobin synthesis in mammals, we sought to evaluate the feasibility of using the canine as a model for studying the homeostasis of erythropoiesis. The canine HRI was cloned, expressed by *in vitro* transcription and translation in wheat germ lysate and also in baculovirus protein expression system and then compared to the murine and human HRI proteins by its functional activity and inhibition by a kinase inhibitor. Additionally, the function of HRI on protein synthesis was evaluated in canine blood with the kinase inhibitor, quercetin.

2. Material and Methods

2.1. Tissue Isolation and Total RNA Preparation. All procedures were performed according to the internationally accepted guidelines for the care and use of laboratory animals in research and were approved by the local International Animal Care and Use Committee. Canine spleen was collected and RNA stabilization was achieved by submersion of tissue in *RNAlater* (Ambion, Milan, Italy). Total cellular RNA (tc-RNA) from spleen was extracted using the RNeasy kit following manufacturer's instructions (Qiagen, Chatsworth, Calif, USA).

2.2. Cloning of Canine HRI cDNA. Reverse transcription (RT) reactions on human (Clontech, Mountain View, Calif, USA) and canine tc-RNA were performed in a 20 μ L reaction mixture containing 10 mM Tris-HCl (pH 8.4), 50 mM KCl, 5 mM MgCl₂, 500 μ M dNTP, 1.25 μ M of oligo(dT) primer, 5 μ g tc-RNA, 40 U of RNase inhibitor, 2 U of RNaseH, and 50 U of reverse transcriptase II (Invitrogen, Carlsbad, Calif, USA). The RT reactions were performed under the following conditions: 90 minutes at 42°C, 10 minutes at 70°C, followed by 20 minutes at 37°C. The resulting cDNA samples (1 μ L) were used for PCR amplification with the addition of 45 μ L of Supermix (Invitrogen, Carlsbad, Calif, USA) containing 2.2 U of Taq DNA polymerase (a mixture of recombinant Taq DNA polymerase and DNA polymerase from pyrococcus species GB-D) in 66 mM Tris-SO₄ (pH 9.1 at 25°C), 19.8 mM (NH₄)₂SO₄, 2.2 mM MgSO₄, 220 μ M dGTP, 220 μ M dATP, 220 μ M dTTP, 220 μ M dCTP, with stabilizers and 20 μ M of sense [5'-AACGTT GAATTCGCC ACC ATG CTG GGG GGC AGCTCCGGT-3'] and antisense primers [5'-AACGTT GCGGCCGCTTAAGG CAGGACGGGCACAGTC-3']. Oligonucleotide primers were designed to be homologous to the corresponding region of the human HRI (GenBank Accession Number: NM_014413). The cDNA fragments were amplified by PCR under the following conditions: 30 s at 94°C for 1 cycle, followed by 94°C for 30 seconds, 30 seconds at 60°C, 72°C for 3 minutes for 30 cycles.

2.3. Cloning of Canine HRI cDNA into Expression Vectors. Two chimeric oligonucleotide primers (described earlier)

were synthesized to facilitate the sub-cloning step (Allele Biotech, San Diego, Calif, USA). The chimeric 5' primer included three adjacent upstream nucleotides; 6 random bp followed by a 6bp EcoRI restriction enzyme sequence and a 6bp Kozak sequence leading to the 21 nucleotides complementary to the canine HRI cDNA sequence. The chimeric 3' primer included 6 random bp followed by a 6bp NotI restriction enzyme sequence and 22 bp complementary to the canine HRI cDNA sequence. PCR with the above 2 chimeric primers resulted in a 1925 bp product, consisting of full length HRI and the sequences corresponding to the chimeric primers.

2.4. Sequencing. Recombinant double-stranded plasmids containing the 1893 bp full-length HRI cDNA insert served as templates for cycle sequencing with specific forward and reverse primers and fluorescence-based dideoxynucleotides, using the dideoxy-terminator cycle sequencing kit (Perkin Elmer, Applied Biosystems, Foster City, Calif, USA). HRI cDNA sequences were determined by the use of a DNA Sequencer (ABI Model 373, Applied Biosystems). Canine HRI cDNA sequences were validated by sequencing cDNA products from three separate RT-PCR reactions, primers were for the forward reaction: 5'-ATCTGATGTCCCAGCAGAACTCCA-3', 5'-GAT ACG GAA GAG TGT ACA AGG TCA-3', 5'-AGG ATC CGACTATGACGCC-3', and 5'-TGCACATCCAGATGCAG CTGTGT-3', and for the reverse: 5'-GAG CTC TAG CAGGATCACACCC-3', 5'-GAT CTT GTG CAT GGG TCA CGTGAA-3', 5'-GCTGGGACATCAGATTCATCATACT-3', (all primers purchased from Allele Biotech).

2.5. Preparation of Recombinant HRI Baculovirus and Expression of Canine HRI Protein in Sf9 Cells. Expression of canine HRI protein (cHRI) in Sf9 cells was achieved using the protocol from a commercially available Bac-n-Bac transfection kit (Invitrogen). The pFastBac transfer vector, in which the canine HRI cDNA was inserted, was transformed into DH10Bac competent cells containing bacmid DNA and a helper plasmid. Cells were incubated on ice for 30 minutes followed by 60 seconds at 42°C allowed for transposition of the pFastBac-cHRI plasmid with the bacmid catalyzed by the transposition sequences on the helper plasmid. Colonies containing recombinant bacmids were identified by selection of blue/white colonies caused by disruption of the lacZ α gene following the cHRI cDNA insertion.

The bacmid DNA was isolated and then transfected into Sf9 cells to make recombinant baculovirus as previously described [9]. Sf9 cells were grown in Sf-900 II serum-free medium in suspension cultures with continuous shaking (150 rpm). Cultures were infected in log phase of growth with recombinant baculovirus at the multiplicity of infection of 3.0. Cells were harvested after 48 hours of infection, washed in phosphate buffered saline solution, resuspended in 1 volume of buffer (10 mM Hepes, pH 7.5, 300 mM NaCl, 5 mM MgCl₂, 10% glycerol) containing protease inhibitor mixture, and ruptured by sonication. The lysate was then

centrifuged at 17,000 ×g for 20 minutes at 4°C and the supernatant collected.

2.6. Purification of Canine HRI Protein. Canine, mouse, rat and human HRI proteins were expressed in Sf9 cells and purified by Ni-NTA affinity chromatography (Qiagen, Valencia, Calif, USA) according to the manufacturer's recommendations and dialyzed in buffer (5 mM Hepes, pH 7.4, 100 mM NaCl, 2 mM DTT) overnight. The canine HRI protein was separated by SDS-PAGE and identified by Western blotting using a mouse anti-histidine primary antibody at 1:1000 (Clontech, Mountain View, Calif, USA) and a secondary anti-mouse HRP conjugated antibody at 1:10,000 (Pierce Biotechnology, Rockford, Ill, USA) followed by enhanced chemiluminescence using the Amersham Enhanced Chemiluminescence Plus Western blotting detection system (GE Biosciences, Piscataway, NJ, USA).

2.7. Expression of Canine HRI Protein by TNT. The cloned canine HRI in the pcDNA4 vector was linearized with NotI and 2.8 μg of the linearized DNA was used for transcription/translation (TNT). Protein expression of the canine HRI was achieved using the cell-free expression kit from Promega using wheat germ lysate according to the manufacturer's protocol. The reaction mix was supplemented with 0.5 mM hemin to increase expression of functional kinase. The [³⁵S]-canine HRI was immunoprecipitated with an anti-histidine antibody bound to protein A-sepharose and then separated on a 4–20% PAGE and visualized by autoradiography.

2.8. Kinase Activity Determination of Purified Canine HRI Protein. The purified canine HRI protein was used to determine its kinase activity in a nonradioactive, phosphorylation-dependent, homogeneous assay, AlphaScreen [10]. Briefly, biotinylated HRI substrate, Poly-GT (Cisbio International, Bedford, Mass, USA) was incubated with purified cHRI kinase for 2 hours at room temperature, in the presence of 4 μM ATP, and 5 mM Mg²⁺/Mn²⁺ allowing for substrate phosphorylation by cHRI. AlphaScreen donor and acceptor beads were then added to the reaction mix according to the manufacturer's protocol (Perkin-Elmer, Waltham, Mass, USA). Kinase activity was determined by detecting an output signal at 540 nm wavelength, with signal intensity being directly proportional to phosphorylated substrate.

For inhibition studies, quercetin (Sigma Chemicals, St. Louis, Mo, USA) was incubated with the kinase in the kinase activity assay as detailed earlier. Inhibition of phosphorylation by the inhibitor was measured as a decrease in AlphaScreen signal. The pIC₅₀ values were determined by fitting a three-parameter logistic function using GraphPad Prism, version 4.02 (Graph Pad Software, San Diego, Calif, USA). Data are presented as mean ± SEM of triplicate values.


2.9. Protein Synthesis in Peripheral Canine Blood. Whole blood from beagle obtained from Bioreclamation (Hicksville,

NY, USA) was washed twice with ice-cold PBS containing 5 mM glucose by centrifuging at 2000 rpm for 5 minutes at 4°C to remove platelets and clotting factors and was passed through a cell strainer (70 μM pore size, BD Biosciences, Lexington, Ky, USA) to remove any clots. The blood cell pellet was then resuspended in pre-warmed (37°C) methionine-free DMEM (Hyclone, Logan, Utah, USA) containing 2 mM glutamine and was treated with either vehicle (1% DMSO) or quercetin in the presence of 0.2 mCi [³⁵S]-methionine (Amersham Bioscience Inc., Piscataway, NJ, USA) for 4 hours at 37°C in 50 mL centrifuge tubes. The samples were swirled every 30 minutes to ensure adequate mixing. After labeling, the cells were transferred to Eppendorf tubes and washed with ice-cold PBS by centrifugation at 14,000 rpm for 5 minutes at 4°C. The cell pellets were lysed in 1 mL of PBS containing 1% Triton X-100. To remove free [³⁵S]-methionine, the lysates were subjected to TCA precipitation and centrifuged at 14,000 rpm for 10 minutes at 4°C. Methionine incorporation into protein was determined by addition of Scintiverse liquid scintillation cocktail and then the [³⁵S] signal was measured using a beta-counter (Beckman Coulter, Fullerton, Calif, USA).

3. Results

3.1. Cloning and Sequence Comparison of Canine HRI cDNA with Other Mammalian HRI. To decide which canine tissues to use for cloning canine HRI cDNA, we performed RT-PCR for HRI using human liver, kidney, lymph node or spleen (Clontech, Mountain View, Calif, USA). As shown in Figure 1(a), HRI was detected in liver, lymph node, and spleen, but not detected in the kidney. Because previous reports demonstrated that HRI is predominantly expressed in erythroid-derived cells [6, 7], we presume that the presence of peripheral blood in the tissues allowed for the detection of HRI. Based on the tissue expression results of the human HRI we decided to clone the canine HRI from canine spleen.

To clone canine HRI cDNA, we prepared total RNA from canine spleen followed by first strand cDNA synthesis using oligo(dT) primers (Invitrogen). The resulting cDNA was used in RT-PCR with cloning primers designed based on the canine genomic sequence corresponding to the human HRI sequence. A PCR fragment of the expected 1925 bp was amplified (Figure 1(b)). The resulting fragment was sequenced and confirmed to be the canine HRI (GenBank Accession Number FJ911905), showing 86% identity in nucleotide sequence to the human, 82% identity to the mouse and 81% identity to the rat HRI (Figure 1(c)). At the amino acid level the canine protein shows 83% identity to the human HRI sequence (NM.014413) and 81% to the mouse (NM.013557) and rat HRI (NM.013223) (Figure 1(d)). As shown in Figure 1(e), the canine sequence shows only 1 amino acid difference in the ATP-binding site compared to the human sequence. The high conservation in the residues involved in ATP binding between the human, canine and rodent proteins is consistent with the functional importance of HRI and its conservation throughout evolution.



Canine	ATGCTGGGGGGCAGCTCCGGTGCCCGAGAGCGCGAGGCGGAGGGCGACGGGGCGGAGGCT	60
Human	ATGCAGGGGGGCAACTCCGGGTCCGCAAGCGCGAAGAGGAGGGCGACGGGGCTGGGGCT	60
Rat	ATGCTGGGGGGCGGCTCCGTGGATGGCGAGCGGACACGGACGACGACGGGGCGGGGCG	60
Mouse	ATGCTGGGGGGCAGCTCCGTGGACGGCGAGCGGACACGGACGACGACGGGGCGGGGGCG	60
	* * * * *	
Canine	GTGCCTGCGCCTCCTGCCATCGAGTTCGGGCGGACGGCTCGGACCCCAAGTATGATGAA	120
Human	GTGGCTGCGCCCGCGCCATCGACTTCCCGCGAGGGCCCGGACCCCGAATATGACGAA	120
Rat	GTGGCCGCGCCTCCTGCCATCGACTTCCCGCAGAGGTGTCGGACCCCAAGTATGATGAG	120
Mouse	GTGGCCGCGCCTCCTGCCATCGACTTCCCGCAGAGGTGTCGGACCCCAAGTATGATGAG	120
	* * * * *	
Canine	TCTGATGTCCCAGCAGAACTCCAAGTATTTAAAAGGACCCCTACAACAGCCGACTTTCCT	180
Human	TCTGATGTTCCAGCAGAAATCCAGGTGTTAAAAGAACCCTACAACAGCCAACTTTCCT	180
Rat	TCCGATGTCCCAGCAGAGCTCCAAGTGTCAAAGAGCCCTTGCAGCAGCCACGTTTCCT	180
Mouse	TCCGATGTCCCAGCAGAGCTCCAAGTGTAAAAGAGCCCTACAGCAGCCACGTTTCCT	180
	* * * * *	
Canine	TTTGCAGTTGCAAACCAACTCTTGCTCGTCTCTTTGCTGGAGCACTTGAGCCATGTGCAT	240
Human	TTTGCAGTTGCAAACCAACTCTTGCTGGTTTCTTTGCTGGAGCACTTGAGCCACGTGCAT	240
Rat	TTCTTAGTGGCAAACAGCTGCTGCTGGTCTCCTTGTGGAACACTTGAGCCATGTGCAT	240
Mouse	TTCTGGTGGCAAACAGCTGCTGCTCCTTACTGGAACACTTGAGCCATGTGCAT	240
	* * * * *	
Canine	GAACCAAACCCGCTCCGTTCAAGACAGGTGTTTAAATTGCTTTGCCAGACGTTTTATCAA	300
Human	GAACCAAACCCACTTCGTTCAAGACAGGTGTTTAAAGTACTTTGCCAGACGTTTTATCAA	300
Rat	GAGCCGAACCCACTTCACTCAAAACAGGTCTTTAAATTAAGTGTGCCAGACTTTTATCAA	300
Mouse	GAGCCAAACCCGCTCCACTCCAACAGGTGTTTAAATTAAGTGTGCCAGACTTTTATCAA	300
	* * * * *	
Canine	ATGGGGCTGCTGTCTTCTTTACCTGTAGTGATGAGTTTAGCTCATTGAGGTACATCAC	360
Human	ATGGGGCTGCTGTCTTCTTTCACTTGTAGTGACGAGTTTAGCTCATTGAGACTACATCAC	360
Rat	ATGGGGCTGCTCTTCTTTACCTGCAGCATGAGTTCAGTCCCTGAGACTCCACCAC	360
Mouse	ATGGGGCTGCTCTTCTTTACCTGCAGTGATGAGTTTAGCTCCTGAGACTCCACCAC	360
	* * * * *	
Canine	AACAGAGCTATTACTCATTTAATGAGATCTGTCTAAAGAGAGAGTTCGTCAGGATCCTTGT	420
Human	AACAGAGCTATTACTCATTTAATGAGGTCTGTCTAAAGAGAGAGTTCGTCAGGATCCTTGT	420
Rat	AACAGAGCCATCACTCATTTAATGAGGTCTGCCAAGGAGAGAGTCCGTCAGGATCCTTGT	420
Mouse	AACAGAGCCATCACTCATTTAATGAGGTCTGCCAAGGAGAGAGTCCGTCAGGATCCTTGT	420
	* * * * *	
Canine	GAAGATAATTCTCATACCCAGAAGATCAGATCAAGGAAATAGCCTTTGAAGCAGACT	480
Human	GAGGATATTTCTCGTATCCAGAAAATCAGATCAAGGAAAGTAGCCTTTGAAGCAGAACT	480
Rat	CAAGATAATTCTTACATGCAGAAAATCAGATCCAGGGAGATAGCTCTCGAAGCAGACT	480
Mouse	CAAGATAATTCTTACATGCAGAAAATCAGATCCAGAGAGATAGCCTTCGAAGCAGAAACG	480
	* * * * *	
Canine	TCACGTTACCTAAATGAATTTGAAGAGCTTGCTGTCTTAGGCAAAGGTGGATACGGAAGA	540
Human	TCACGTTACTTAAATGAATTTGAAGAACTTGCCATCTTAGGAAAAGGTGGATACGGAAGA	540
Rat	TCACGCTACTTAAATGAATTTGAAGAGCTCGCCATCTTAGGAAAAGGCGGATATGGAAGA	540
Mouse	TCACGCTACTTAAATGAATTTGAAGAGCTTGCCATCTTAGGAAAAGGAGGATATGGAAGA	540
	* * * * *	
Canine	GTGTACAAGGTCAGGAATAAATFAGATGGTCAGTATTATGCAATTAAGAAAATCCTGATT	600
Human	GTATACAAGGTCAGGAATAAATFAGATGGTCAGTATTATGCAATTAAGAAAATCCTGATT	600
Rat	GTTTACAAGGTCAGGAATAAATFAGATGGTCAGCATTATGCAATTAAGAAAATCCTGATT	600
Mouse	GTTTACAAGGTCAGGAATAAATFAGATGGTCAGCATTATGCAATTAAGAAAATCCTGATT	600
	* * * * *	
Canine	AATGGTGCACCTAAAACAGATTGTATGAAGGTACTACGGGAAGTGAAGGTGCTGGCAGGC	660
Human	AAGGTGCACCTAAAACAGTTTGCATGAAGGTCTACGGGAAGTGAAGGTGCTGGCAGGT	660
Rat	AAGAGTGCACCTAAAACAGATTGTATGAAGGTGCTACGGGAAGTGAAGGTGCTGGCAGGC	660
Mouse	AAGAGCGCACTAAAACAGATTGTATGAAGGTGCTACGGGAAGTGAAGGTGCTGGCAGGT	660
	* * * * *	
Canine	CTTCAGCATCCTAACATAGTAGGCTATCACACTGCTTGGATAGAACATGTTACAGTGACC	720
Human	CTTCAGCACCCCAATATTGTTGGCTATCACACCGCGTGGATAGAACATGTTACATGTGATT	720
Rat	CTCCAGCACCCCAATATCGTTGGCTACCACACTGCATGGATAGAGCAGTTACAGTGCTT	720
Mouse	CTCCAGCATCCTAACATATTGTTGGCTACCACACTGCGTGGATAGAACATGTTACATGTGTT	720
	* * * * *	
Canine	CATGCACAAG - - - ATCGAATTCTATTACAGCTGCCATCTCTGGAAGTGATCTCTGACGAG	777
Human	CAGCCACGAGCAGACAGAGCTGCCATTGAGTTGCCATCTCTGGAAGTGCTCTCCGACGAG	777
Rat	CAGCCACAAG - - - ACAGAGTTCACATTCACACTGCCCTCTCTTGAAGTGTGTCAGAGCAT	780
Mouse	CAGCCACAAG - - - ACAGAGTTCAGATTCAACTGCCCTCTCTCGAAGTGCTGTGCGAGCAG	777
	* * * * *	

FIGURE 1: Continued.

Canine	GAGGGTGACAGAAATCAACATG - - - TAAAAATGATGAAAGT AACAGCTCATCCATTATC	834
Human	GAAGAGGACAGAGACCAATGTGGTGT TAAAAATGATGAAAGTACAGCTCATCCATTATC	840
Rat	GAAGGGGACAGAAATCAAGGTGGTGT TAAAAATGATGAAAG - - - CAGTTCGTCCATTATC	834
Mouse	GAAGGGGACAGAGACCAAGGTGGTGT TAAAAATGATGAAAG - - - CAGTTCGTCCATTATC	834
	* * * * *	
Canine	TTCCGCCGAGTTACCTCAGGAAAAAGACAAATCCTTAGGAAAAATCTGGCATTGAAAATCGG	894
Human	TTTGGCTGAGCCACCCAGAAAAAGAAAAACGCTTTGGAGAAATCTGACACTGAAAATCAG	900
Rat	TTTGGCTGAACTCACCCAGAAAAAGAAAAACCTTTAGCGGAATCTGATGTTAAGAATGAG	894
Mouse	TTTGGCTGAACTCACCCAGAAAAAGAAAAACCTTTTGGGGAGTCTGAGGTTAAAAATGAG	894
	* * * * *	
Canine	AATAATAGATTGGTGAAGTACAGCACCAGTTAATCCCCAGAGACACCAGTGAATTTGAA	954
Human	AATAACAAGTCGGTGAAGTACACCACCAATTTAGTCATAAGAGAATCTGGTGAACCTTGAG	960
Rat	AATAACAACCTGGTGAAGTACAGGGCCAACCTTAGTGATCAGGAGCAGCAGTGAAGCGAA	954
Mouse	AATAACAACCTGGTGAAGTACAGGGCCAACCTTAGTGGTCAGGAACAGCAGTGAAGTGAA	954
	* * * * *	
Canine	TCACCCAGTTTTCTCCAAAGAAATGGTTGGCTGATTTGCCTTCCAGCTCAATATTGAA	1014
Human	TCGACCCCTGGAGCTCCAGGAAAAATGGCTTGGCTGGTTTGTCTGCCAGTTCAATTTGGAA	1020
Rat	TCGTCCATTGAGCTCCAAGAAGATGGCTTGAACGAGTCCGCTCTCAGACCAGTTGTCAG	1014
Mouse	TCGTCCATTGAGCTCCAAGAAGACGGCTTGACTGATTTGTCCGTGAGACCAGTTGTCAGG	1014
	* * * * *	
Canine	CATCAGCTGCCACTTAGGCATCATTCCGACTTAGAAGAGAATTTACATCCACTGGGGAA	1074
Human	CAGCAGCTGCCACTCAGGCCTAATCCACCTAGAGGAGAGTTTACATCCACCAGAAAGAA	1080
Rat	CACACGCTGCCGCTGGGGCATAGCTCAGCAGTGAAGGGAATTTTACCTCCACGGATGAG	1074
Mouse	CATCAGCTGCCGCTGGGGCATAGCTCGGAAATTTGAAGGGAATTTTACATCCACCAGTGA	1074
	* * * * *	
Canine	TCTTCTGAA - - - AACTTAAGTTTTGTGGGGCAGACAGAGGTGCAGTACCACCTGATGCTG	1131
Human	TCTTCCGAAGAAAATGTCAACTTTTTGGGTGAGACAGAGGCACAGTACCACCTGATGCTG	1140
Rat	TCTTCTGAAGACAATTTGAACCTGCTGGGGCAGACAGAGGCGGGTACCACCTGATGCTG	1134
Mouse	TCTTCTGAAGGCAACTTGAACCTGCTGGGGCAGACGAGGTTCCGTTACCACCTGATGTTG	1134
	* * * * *	
Canine	CACATCCAGATGCAGCTGTGTGAGCTCTCCCTGTGGGACTGGATAGTGGAGAGAAACCAG	1191
Human	CACATCCAGATGCAGCTGTGTGAGCTCTCCCTGTGGGACTGGATAGTGGAGAGAAACAAG	1200
Rat	CACATCCAGATGCAGCTGTGTGAGCTCTCCCTGTGGGACTGGATAGTGGAGAGAAACAAG	1194
Mouse	CACATCCAGATGCAGCTGTGTGAGCTCTCCCTGTGGGACTGGATAACTGGAGAGAAACAAG	1194
	* * * * *	
Canine	CGGGGTCGGCAGTATGTGGACGAATCTGCATGTCCTTATGTCATGGCCAGTGTGCAACA	1251
Human	CGGGGTCGGGAGTATGTGGACGAGTCTGCCTGTCCCTATGTTATGGCCAAATGTTGCAACA	1260
Rat	CGGAGCCGGAAGTGCCTGGATGAAGCAGCTTGTCCCTATGTTATGGCCAGTGTGCAACA	1254
Mouse	CGGAGCCGGAAGTATGTGGACGAAGCTGCTTGTCCCTATGTTATGGCCAGTGTGCAACA	1254
	* * * * *	
Canine	AAGATTTTTCAAGAAGTGGTGAAGGTGTATTTTACATACATAACATGGGAATCGTACAC	1311
Human	AAAATTTTTCAAGAATTTGGTAGAAGGTGTGTTTTACATACATAACATGGGAATTTGTCAC	1320
Rat	AAGATTTTTCAAGAAGTGGTGAAGGTGTCTTTTACATACATAACATGGGCATCGTCCAC	1314
Mouse	AAAATTTTTCAAGAATTTGGTGAAGGTGTCTTTTACATACATAACATGGGCATTTGTCAC	1314
	* * * * *	
Canine	AGAGATCTGAAGCCAAGAAATATTTTTCTTCATGGCCCTGATCAGCAAGTAAAAATAGGA	1371
Human	CGAGATCTGAAGCCAAGAAATATTTTTCTTCATGGCCCTGATCAGCAAGTAAAAATAGGA	1380
Rat	AGAGATCTGAAGCCTAGAAATATTTTTCTTCATGGTCCCTGATCAACAAGTAAAAATAGGA	1374
Mouse	AGAGATCTGAAGCCTAGAAATATTTTTCTTCATGGCCCTGATCAGCAAGTAAAAATAGGA	1374
	* * * * *	
Canine	GACTTTGGTCTGGCCTGCACAGACATCATTCAAAGAACACAGACTGGATCGGTAGAGAT	1431
Human	GACTTTGGTCTGGCCTGCACAGACATCCTACAGAAGAACACAGACTGGACCAACAGAAAC	1440
Rat	GACTTTGGTCTGGCCTGTGCAGACATCATTCAAGAAGCGCAGATTGGACCAACAGAAAC	1434
Mouse	GACTTTGGTCTGGCCTGTGCAGACATCATCCAGAA - - - TGCAGACTGGACCAACAGAAAT	1431
	* * * * *	
Canine	GGGAAGAGGCCACCCACACACACTTCCAGAGTGGGACTTGTCTATACGCTTACCTGAG	1491
Human	GGGAAGAGAACACCAACACATACGTCCAGAGTGGGACTTGTCTGTACGCTTACCCCGAA	1500
Rat	GGGAAGGAACGCCGACACACACAGTCCCGAGTGGGACTTGTCTCTACGGCTCAGCTGAG	1494
Mouse	GGGAAGGAACACGGACACACACATCCAGAGTGGGACTTGTCTCTACGCATCACCGGAA	1491
	* * * * *	
Canine	CAGTTGGAAGGATCCGACTATGACGCCAAGTCAGATATGTACAGCTTGGGTGTGATCCTG	1551
Human	CAGTTGGAAGGATCTGAGTATGATGCCAAGTCAGATATGTACAGCTTGGGTGTGGTCTCTG	1560
Rat	CAGTTGGAAGGATCCGAGTATGATGCCAAGTCTGATATGTACAGCTTGGGTGTGATCCTG	1554
Mouse	CAGCTGGAGGGATCCAGTACGATGCCAAGTCAGATATGTATAGCTTGGGTGTGATCCTG	1551
	* * * * *	
Canine	CTAGAGCTCTTTTACGCCATTTGGAACAGAAATGGAGCGAGTACACATTTTAAACAGGTTTA	1611
Human	CTAGAGCTCTTTTACGCCGTTTGGAAACAGAAATGGAGCGAGCAGAAAGTTCTAACAGGTTTA	1620
Rat	CTCGAGCTCTTTTACGCCATTTGGGAACAGAAATGGAGCGAGCAACAGTCTAACAGGTTG	1614
Mouse	CTCGAGCTCTTTTACGCCATTTGGGAACAGAAATGGAGAGGGCAACAGTCTTAAACAGGCTA	1611
	* * * * *	
Canine	AGAAGTGGTCAGATACCTGACTCCCTCAGTAAAGAGGTGTCCCGTGCAAGCCAAGTACATC	1671
Human	AGAACTGGTCAGTTGCCGGAATCCCTCCGTAAAAAGTGTCCAGTGCAAGCCAAGTATATC	1680
Rat	AGGACTGGTCGGATACCCAGTCCCTCAGTAAAGAGTGTCCAGTGCAAGCCAAGTATATC	1674
Mouse	AGGACTGGTCGGATACCCGAATCCCTCAGTAAAGAGTGTCCCGTGCAAGCCAAGTATATC	1671
	* * * * *	
Canine	CAGCACTTAACAGAGAAGGAATGCATCTCAGAGACCATCTGCTCTTTCAGCTGCTGCAAAGT	1731
Human	CAGCACTTAACAGAGAAGGAATGCATCTCAGAGACCATCTGCCATTTCAGCTGCTGCAAGT	1740
Rat	CAGCTCTGACTGGGAGGAACGCCGCCAGAGACCATCTGCTCTTTCAGCTACTGCAAGG	1734
Mouse	CAGCTCTAACCAGGAGGAATGTGTACAGAGACCATCTGCCCTTTCAGCTGCTGCAAGT	1731
	* * * * *	

FIGURE 1: Continued.

Canine GAACTTTTCCAAAATTCTGGAAATGTTAACCTCACCCCTACAGATGAAAATACTAGAGCAA 1791
Human GAACTTTTCCAAAATTCTGGAAATGTTAACCTCACCCCTACAGATGAAGATAATAGAGCAA 1800
Rat GAACTGTTCCAAAACAACCGGAAATGTTAATCTCACATTGCAGATGAAGATAATGGAGCAA 1794
Mouse GAGCTTTTTCAAAACAACCTGGAAATGTTAATCTCACATTGCAGATGAAGATAATAGAACAA 1791
* * * * *

Canine GAAAAAGAAATCGAAGAACTAAAGAAGCAGCTGAGTCTCCTTTCTCAGGACAAAAGGGGCC 1851
Human GAAAAAGAAATTCGAGAACTAAAGAAGCAGCTAAACCTCCTTTCTCAAGACAAAAGGGGTG 1860
Rat GAAAAAGAAATTAAGAATTAAGAAGCAACTAAGCCTCCTTTTCGAGGACAAAAGGGCTG 1854
Mouse GAGAAGGAAATTAAGAACTAAAGAAGCAACTAAGCCTCCTTTCTCAGGACAGAGGGCTG 1851
* * * * *

Canine AAG - GATGATATGAAGGATGGGACTGTGCCCGTCTGCCTTAA 1893
Human AGG - GATGACGAAAGGATGGGGCGTGGGATGA - - - - - 1893
Rat AAGAGATGA - - - - - 1863
Mouse AAGAGATGA - - - - - 1860
* * * * *

(c)

Mouse MLGGSVDGERDTHDDAAGVAAPPAIDFPAEVS DPKYDES DVPAELQVLKEP LQQPTFP 60
Rat MLGGGSVDGERDTHDDAAGVAAPPAIDFPAEVS DPKYDES DVPAELQVFKEP LQQPTFP 60
Canine MLGGSVGAREREAEGDGAEAVPAPPAIEFPADGSDPKYDES DVPAELQVLKGP LQQPTFP 60
Human MQGGNSGVRKREEEGDGAGVAAPPAIDFPAEGDPPEYDES DVPAELQVLKEP LQQPTFP 60
* * * * * : * : . * . * * * . * * * * * : * * * * * : * * * * * : * * * * * : * * * * *

N-terminal heme binding domain

Mouse F L V A N Q L L L V S L L E H L S H V H E P N P L H S K Q V F K L L C Q T F I K M G L L S S F T C S D E F S S L R L H H 120
Rat F L V A N Q L L L V S L L E H L S H V H E P N P L H S K Q V F K L L C Q T F I K M G L L S S F T C S D E F S S L R L H H 120
Canine F A V A N Q L L L V S L L E H L S H V H E P N P L R S R Q V F K L L C Q T F I K M G L L S S F T C S D E F S S L R L H H 120
Human F A V A N Q L L L V S L L E H L S H V H E P N P L R S R Q V F K L L C Q T F I K M G L L S S F T C S D E F S S L R L H H 120
* * * * * : * : * * * * * : * * * * * : * * * * * : * * * * *

Mouse N R A I T H L M R S A K E R V R Q D P C Q D N S Y M Q K I R S R E I A F E A Q T S R Y L N E F E E L A I L G K G G Y G R 180
Rat N R A I T H L M R S A K E R V R Q D P C Q D N S Y M Q K I R S R E I A L E A Q T S R Y L N E F E E L A I L G K G G Y G R 180
Canine N R A I T H L M R S A K E R V R Q D P C E D N S H T Q K I R S R E I A F E A Q T S R Y L N E F E E L A V L G K G G Y G R 180
Human N R A I T H L M R S A K E R V R Q D P C E D I S R I Q K I R S R E V A L E A Q T S R Y L N E F E E L A I L G K G G Y G R 180
* * * * * : * : * * * * * : * * * * * : * * * * * : * * * * *

Mouse V Y K V R N K L D G Q H Y A I K K I L I K S A T K T D C M K V L R E V K V L A G L Q H P N I V G Y H T A W I E H V H V V 240
Rat V Y K V R N K L D G Q H Y A I K K I L I K S A T K T D C M K V L R E V K V L A G L Q H P N I V G Y H T A W I E H V H V L 240
Canine V Y K V R N K L D G Q Y Y A I K K I L I N G A T K T D C M K V L R E V K V L A G L Q H P N I V G Y H T A W I E H V H V T 240
Human V Y K V R N K L D G Q Y Y A I K K I L I K G A T K T V C M K V L R E V K V L A G L Q H P N I V G Y H T A W I E H V H V I 240
* * * * * : * * * * * : * * * * * : * * * * * : * * * * *

Mouse Q P - Q D R V P I Q L P S L E V L S E Q E G D R D Q G G V K D N E S - S S S I V F A E L T P E K E K P F G E S E V K N E 298
Rat Q P - Q D R V P I Q L P S L E V L S E H E G D R N Q G G V K D N E S - S S S I F A E L T P E K E N P L A E S D V K N E 298
Canine H A - Q D R I S I Q L P S L E V I S D E E G D R N Q H - V K N D E S N S S S I F A E F T S G K D K S L G K S G I E N R 298
Human Q P R A D R A A I E L P S L E V L S D Q E E D R E Q C G V K N D E S S S S S I F A E P T P E K E K R F G E S D T E N Q 300
: * * * * : * * * * * : * * * * * : * * * * * : * * * * * : * * * * * : * * * * * : * * * * * : * * * * *

Mouse N N N L V S Y R A N L V I R S S S E S S I E L Q E D G L T D L S V R P V V R H Q L P L G H S S E L E G N F T S T D E 358
Rat N N N L V S Y R A N L V I R S S S E S S I E L Q E D G L N E S P L R P V V K H Q L P L G H S S D V E G N F T S T D E 358
Canine N N R L V N Y S T S L I P R D T S E F E S P S F L Q R N G L A D L P S S S I I E H Q L P L R H H S D L E E N F T S T G E 358
Human N N K S V K Y T T N L V I R E S G E L E S T L E L Q E N G L A G L S A S S I V E Q Q L P L R R N S H L E E S F T S T E E 360
* * * * * : * : * * * * * : * * * * * : * * * * * : * * * * * : * * * * *

Heme

Mouse S S E G N L N L L G Q T E V R Y H L M L H I Q M Q L C E L S L W D W I T E R N K R S R E Y V D E A A C P Y V M A S V A T 418
Rat S S E D N L N L L G Q T E A R Y H L M L H I Q M Q L C E L S L W D W I A E R N K R S R K C V D E A A C P Y V M A S V A T 418
Canine S S E - N L S L L G Q T E V Q Y H L M L H I Q M Q L C E L S L W D W I V E R N Q R G R Q Y V D E S A C P Y V M A S V A T 417
Human S S E E N V N F L G Q T E A Q Y H L M L H I Q M Q L C E L S L W D W I V E R N K R G R E Y V D E S A C P Y V M A N V A T 420
* * * * * : * : * * * * * : * * * * * : * * * * * : * * * * * : * * * * *

Mouse K I F Q E L V E G V F Y I H N M G I V H R D L K P R N I F L H G P D Q Q V K I G D F G L A C A D I I Q N - A D W T N R N 477
Rat K I F Q E L V E G V F Y I H N M G I V H R D L K P R N I F L H G P D Q Q V K I G D F G L A C A D I I Q K S A D W T N R N 478
Canine K I F Q E L V E G V F Y I H N M G I V H R D L K P R N I F L H G P D Q Q V K I G D F G L A C T D I I Q K N T D W I G R D 477
Human K I F Q E L V E G V F Y I H N M G I V H R D L K P R N I F L H G P D Q Q V K I G D F G L A C T D I L Q K N T D W T N R N 480
* * * * * : * : * * * * * : * * * * * : * * * * * : * * * * * : * * * * *

Mouse G K G T R T H T S R V G T C L Y A S P E Q L E G S Y D A K S D M Y S L G V I L L E L F Q P F G T E M E R A T V L T G V 537
Rat G K G T P T H T S R V G T C L Y A S P E Q L E G S E Y D A K S D M Y S L G V I L L E L F Q P F G T E M E R A T V L T G V 538
Canine G K R P P T H T S R V G T C L Y A S P E Q L E G S D Y D A K S D M Y S L G V I L L E L F Q P F G T E M E R V H I L T G L 537
Human G K R T P T H T S R V G T C L Y A S P E Q L E G S E Y D A K S D M Y S L G V V L L E L F Q P F G T E M E R A E V L T G L 540
* * * * * : * : * * * * * : * * * * * : * * * * * : * * * * * : * * * * *

Mouse R T G R I P E S L S K R C P V Q A K Y I Q L L T G R N V S Q R P S A L Q L L Q S E L F Q T T G N V N L T L Q M K I I E Q 597
Rat R T G R I P E S L S K R C P V Q A K Y I Q L L T G R N A A Q R P S A L Q L L Q S E L F Q T T G N V N L T L Q M K I M E Q 598
Canine R S G Q I P D S L S K R C P V Q A K Y I Q H L T R R N A S Q R P S A L Q L L Q S E L F Q N S G N V N L T L Q M K I L E Q 597
Human R T G Q L P E S L R K R C P V Q A K Y I Q H L T R R N S S Q R P S A I Q L L Q S E L F Q N S G N V N L T L Q M K I I E Q 600
* * * * * : * : * * * * * : * * * * * : * * * * * : * * * * * : * * * * *

FIGURE 1: Continued.




FIGURE 3: (a) Restriction digestion analysis of the canine HRI-bacmid DNA verifies the insertion of canine HRI cDNA into the bacmid DNA with correct orientation. Lane 1, Molecular Weight markers; Lane 2, pFastBac-canine HRI cDNA. (b) Expression of mammalian HRIs. HRI, expressed in insect cells, was detected by Western blot analysis using an affinity purified mouse monoclonal antibody against histidine and visualized by enhanced chemiluminescence. Lane 1, canine HRI; Lane 2, mouse HRI; Lane 3, rat HRI; Lane 4, human HRI.

3.4. Kinase Activity of the Canine HRI Protein. To determine if the purified canine HRI protein is enzymatically active, we performed a kinase activity assay by measuring the ability of the kinase to phosphorylate a peptide substrate. As shown in Figure 4, the canine HRI protein was able to effectively phosphorylate the peptide substrate. To investigate whether the high degree of homology in the ATP-binding site of canine, human, and rodent HRI results in similar binding of an ATP-competitive kinase inhibitor, we used a known human HRI kinase inhibitor, quercetin ([11] and our published data). Quercetin, reported to be an ATP-competitive kinase inhibitor [11], was tested at various concentrations from $0.01 \mu\text{M}$ to $100 \mu\text{M}$ against canine, human, and mouse HRI shown in Figure 5. We found that similar to human and mouse HRI, canine HRI kinase was inhibited with IC_{50} values equal to $\sim 1 \mu\text{M}$ by quercetin, demonstrating that among mammalian HRI, ATP-binding and catalysis are conserved.

3.5. Role of HRI in De Novo Protein Synthesis. To determine the effect of HRI inhibition by quercetin on protein synthesis, we treated canine blood with either 1 or $10 \mu\text{M}$ quercetin for 4 hours in the presence of $[^{35}\text{S}]$ -methionine (Figure 6). Quercetin, at a concentration of $1 \mu\text{M}$, did not change total de novo synthesis in canine blood. However, treatment of canine blood with $10 \mu\text{M}$ quercetin caused a significant increase in de novo protein synthesis compared to the vehicle control. Because HRI is specifically expressed in




FIGURE 4: Kinase activity of recombinant canine HRI. Kinase activity of canine HRI was determined by an in-vitro kinase assay using purified canine HRI and a kinase peptide substrate. The experiment was performed in triplicate with the mean \pm SEM shown.

erythroid cells and $\sim 95\%$ of de novo protein synthesis in late erythroblasts and reticulocytes is globin protein [12], the newly synthesized $[^{35}\text{S}]$ -methionine labeled protein measured is most likely due to de novo hemoglobin synthesis in erythroid cells. Therefore, we conclude that inhibition of HRI by the HRI kinase inhibitor is able to increase hemoglobin synthesis in canine reticulocytes.

4. Discussion

Hemoglobin synthesis in erythroid cells is tightly regulated by heme, because heme binds to HRI and modulates its kinase activity. It has been reported that the enzymatically functional form of HRI is dimeric [7] and remains soluble devoid of aggregation. Maintaining the dimeric form of HRI in order to prevent its aggregation makes HRI a difficult protein to express in large quantities in vitro. We found that HRI is largely misfolded when expressed by in vitro TNT, however, the expression of soluble HRI protein can be improved by supplementing the reaction with heme (Figure 2). In the HRI protein expression conditions used in this study, heme primarily plays a critical role by inactivating newly synthesized HRI by binding to the kinase insert domain. Consequently, heme addition increased protein production. In addition, heme addition appears to improve the yield of soluble protein by preventing newly translated HRI protein from aggregation. It is conceivable that HRI incorporates a heme moiety into the N-terminus of the protein cotranslationally to allow for the proper folding and assembly of the protein. To improve the protein yield of the human, mouse, rat, and canine HRI proteins, we supplemented insect cell culture medium with hemin during HRI protein expression (Figure 3).

A comparison of the mammalian HRI nucleotide and amino acid sequences reveals a high degree of conservation in the residues involved in ATP-binding (Figures 1(c), 1(d), and 1(e)). Specifically, the comparison shows there is only one




FIGURE 5: Inhibition of HRI kinase activity by quercetin. The kinase activity of the purified human, mouse and canine HRI proteins was determined using an in-vitro kinase assay in the presence of various concentrations of quercetin from 0.01 μM to 100 μM , shown in log M units. The data are expressed as a percent of activity compared to a vehicle control at 100% at the end of the two hour reaction. All experiments were performed in duplicate or triplicate with the mean \pm SEM represented.




FIGURE 6: Effect of HRI inhibition on protein synthesis by quercetin in canine blood cells. Total protein synthesis in canine blood was determined by [³⁵S]-methionine incorporation into newly synthesized protein in the presence of 1 or 10 μM quercetin. The amounts of [³⁵S]-methionine incorporation were compared to a vehicle control of 1% DMSO and the fold increase with the mean \pm SEM from replicates is shown.

amino acid residue difference between the human and canine proteins and only two residues between the mouse and canine proteins. Additionally, the residues involved in heme-binding, either in the N-terminal regulatory domain or in the kinase insert domain, are completely conserved between the mammalian proteins, implying that the development and homeostatic regulation of circulatory systems among mammals is subject to the same evolutionary pressure

(Figure 1(d)). As expected from the high degree of sequence homology, we have found that the mammalian HRI proteins show similar ATP affinity with an apparent K_m of $\sim 1\text{-}2\ \mu\text{M}$ (data not shown). The high degree of homology in the catalytic domain is also reflected by the similar potency determined between the mammalian proteins in the ability of quercetin to inhibit HRI kinase activity (Figure 5).

Normal adult hemoglobin consists of two α - and two β -globin subunits and its proper assembly is essential for oxygen transport [5]. The majority (>90%) of actively translating mRNA in reticulocytes is globin mRNA, and 95% of protein made in reticulocytes is globin protein [12]. Translation of α - and β -globin is tightly controlled by eIF2 and downregulated by HRI. By enhancing translation of globin by an HRI inhibitor in reticulocytes, the hemoglobin content of red blood cells is expected to increase causing an increase in the body's oxygen-carrying capacity. In this study, we show that inhibition of HRI by quercetin is able to increase de novo protein translation in canine reticulocytes (Figure 6) and also in mouse and rat reticulocytes (data not shown). Since HRI is predominantly expressed in erythroid cells [5] and since mature red blood cells do not have the ability to synthesize protein, we used the [³⁵S]-methionine incorporation in canine blood as an indirect measure of hemoglobin synthesis in erythroid cells. Our finding that HRI inhibition increases hemoglobin synthesis leads us to propose that antagonism of HRI may be of potential therapeutic importance for the treatment of iron-deficient blood disorders.

This study also shows that the canine HRI is conserved not only in the primary sequence of the gene but also functionally in its role on the regulation of protein synthesis. Together with the advantage of an ample supply of blood and similar physiology between canine and human, canine appears to be a good model species for further elucidation of the role of HRI protein in its contribution to iron-deficient anemias and perhaps other hematologic diseases such as β -thalassemia.

Abbreviations

eIF:	Eukaryotic initiation factor
HRI:	Heme-regulated inhibitor
ATP:	Adenosine tri-phosphate
TNT:	Transcription and translation
Quercetin:	3,3',4',5,7-pentahydroxyflavone
TCA:	Trichloroacetic acid
bp:	Base pair.

Acknowledgment

The authors would like to thank Marcela Alomia for help in performing some of the kinase assays. Kimon C. Kanelakis and Jayashree Pyati contributed equally in this work.

References

- [1] A.-P. Han, C. Yu, L. Lu, et al., "Heme-regulated eIF2 α kinase (HRI) is required for translational regulation and survival of erythroid precursors in iron deficiency," *The EMBO Journal*, vol. 20, no. 23, pp. 6909–6918, 2001.
- [2] G. Manning, D. B. Whyte, R. Martinez, T. Hunter, and S. Sudarsanam, "The protein kinase complement of the human genome," *Science*, vol. 298, no. 5600, pp. 1912–1934, 2002.
- [3] J.-J. Chen, M. S. Throop, L. Gehrke, et al., "Cloning of the cDNA of the heme-regulated eukaryotic initiation factor 2 α (eIF-2 α) kinase of rabbit reticulocytes: homology to yeast GCN2 protein kinase and human double-stranded-RNA-dependent eIF-2 α kinase," *Proceedings of the National Academy of Sciences of the United States of America*, vol. 88, no. 17, pp. 7729–7733, 1991.
- [4] A. Sudhakar, A. Ramachandran, S. Ghosh, S. E. Hasnain, R. J. Kaufman, and K. V. A. Ramaiah, "Phosphorylation of serine 51 in initiation factor 2 α (eIF2 α) promotes complex formation between eIF2 α (P) and eIF2B and causes inhibition in the guanine nucleotide exchange activity of eIF2B," *Biochemistry*, vol. 39, no. 42, pp. 12929–12938, 2000.
- [5] J.-J. Chen and I. M. London, "Regulation of protein synthesis by heme-regulated eIF-2 α kinase," *Trends in Biochemical Sciences*, vol. 20, no. 3, pp. 105–108, 1995.
- [6] J. S. Crosby, K. Lee, I. M. London, and J.-J. Chen, "Erythroid expression of the heme-regulated eIF-2 α kinase," *Molecular and Cellular Biology*, vol. 14, no. 6, pp. 3906–3914, 1994.
- [7] J.-J. Chen, "Regulation of protein synthesis by the heme-regulated eIF2 α kinase: relevance to anemias," *Blood*, vol. 109, no. 7, pp. 2693–2699, 2007.
- [8] J.-J. Chen, "Heme-regulated eIF2 α kinase," in *Translational Control of Gene Expression*, vol. 39 of *Cold Spring Harbor Monograph Series*, pp. 529–546, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY, USA, 2000.
- [9] P. J. Chefalo, J. M. Yang, K. V. A. Ramaiah, L. Gehrke, and J.-J. Chen, "Inhibition of protein synthesis in insect cells by baculovirus-expressed heme-regulated eIF-2 α kinase," *The Journal of Biological Chemistry*, vol. 269, no. 41, pp. 25788–25794, 1994.
- [10] E. F. Ullman, H. Kirakossian, S. Singh, et al., "Luminescent oxygen channeling immunoassay: measurement of particle binding kinetics by chemiluminescence," *Proceedings of the National Academy of Sciences of the United States of America*, vol. 91, no. 12, pp. 5426–5430, 1994.
- [11] A. K. Srivastava and J. L. Chiasson, "Effect of quercetin on serine/threonine and tyrosine protein kinases," *Progress in Clinical and Biological Research*, vol. 213, pp. 315–318, 1986.
- [12] W. R. Woodward, S. D. Adamson, H. M. McQueen, et al., "Globin synthesis on reticulocyte membrane-bound ribosomes," *The Journal of Biological Chemistry*, vol. 248, no. 5, pp. 1556–1561, 1973.